Huang et al(10) reported that benzodithiazolium-based compound CX9051 is a selective inhibitor for Cox-2 activity, which inhibits cell proliferation and induces apoptosis in numerous human cancer cell types including prostate cancer cells. Here, PTGS2 is linked to prostate carcinoma.